These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
| ☐ |
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
|
| ☒ |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2019
|
| ☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
| ☐ |
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report………………..
For the transition period from to
|
|
ISRAEL
|
|
(Jurisdiction of incorporation
or organization)
|
|
None
|
None
|
|
|
Title of each class
|
|
Name of each exchange on which registered
|
|
Ordinary Shares, NIS 0.01 nominal value per share
|
NASDAQ GLOBAL SELECT MARKET
|
|
Large accelerated filer
☐
|
Accelerated filer
☒
|
Non-accelerated filer
☐
|
Emerging growth company
☐
|
| 7 | |
|
7
|
|
|
7
|
|
|
7
|
|
|
A. Selected Financial Data
|
7
|
|
B. Capitalization and Indebtedness
|
10
|
|
C. Reason For the Offer and Use of Proceeds
|
10
|
|
D. Risk Factors
|
10
|
|
30
|
|
|
A. History and Development of the Company
|
30
|
|
B. Business Overview
|
32
|
|
Principal Markets
|
35
|
|
Manufacturing and Suppliers
|
36
|
|
Marketing Channels
|
37
|
|
Patents and Licenses
|
39 |
|
Competition
|
40
|
|
Governmental Regulation Affecting the Company
|
41
|
|
C. Organizational Structure
|
42
|
|
43
|
|
|
43
|
|
|
A. Operating Results
|
46 |
|
B. Liquidity and Capital Resources
|
50
|
|
C. Research and Development, Patents and Licenses, Etc.
|
50
|
|
D. Trend Information
|
53
|
|
E. Off-Balance Sheet Arrangements
|
54
|
|
F. Tabular Disclosure of Contractual Obligations
|
55
|
| 56 | |
|
A. Directors and Senior Management
|
56
|
|
B. Compensation
|
58
|
|
Board of Directors
|
62
|
|
External Directors
|
63 |
|
Audit Committee
|
67
|
|
Compensation Committee
|
68
|
|
D. Employees
|
73
|
|
E. Share Ownership
|
75
|
|
76
|
|
|
A. Major Shareholders
|
76
|
|
B. Related Party Transactions
|
78
|
| ITEM 8. FINANCIAL INFORMATION |
80
|
| A. Consolidated Statements and Other Financial Information |
80
|
| B. Significant Changes |
81
|
|
81
|
|
|
A. Offer and Listing Details
|
81
|
|
Markets and Share Price History
|
81
|
| ITEM 10. ADDITIONAL INFORMATION |
82
|
| A. Share Capital |
82
|
| B. Memorandum and Articles of Association |
82
|
| C. Material Contracts |
92
|
| D. Exchange Controls |
93
|
| E. Taxation |
93
|
| F. Dividends and Paying Agents |
101
|
| G. Statement by Experts |
101
|
| H. Documents on Display |
101
|
| I. Subsidiary Information |
102
|
|
102
|
|
|
Interest Rate Risk
|
102
|
|
Foreign Currency Exchange Risk
|
102
|
|
104
|
|
|
104
|
|
|
104
|
|
|
104
|
|
|
104
|
|
|
Disclosure Controls and Procedures
|
104
|
|
Management's Annual Report on Internal Control over Financial Reporting
|
105
|
|
Inherent Limitations on Effectiveness of Controls
|
105
|
|
Changes in Internal Control over Financial Reporting
|
105
|
|
105
|
|
|
105
|
|
|
105
|
|
106
|
|
|
106
|
|
|
107
|
|
|
107
|
|
|
108
|
|
|
108
|
|
|
110
|
|
|
110
|
|
|
110
|
|
|
110
|
|
|
110
|
|
2015
|
2016
|
2017
|
2018
|
2019
|
||||||||||||||||
|
Sales
|
|
82,738
|
|
100,347
|
125,690
|
133,753
|
105,240
|
|||||||||||||
|
Cost of sales
|
48,659
|
61,796
|
79,762
|
91,697
|
69,146
|
|||||||||||||||
|
Gross profit
|
34,079
|
38,551
|
45,928
|
42,056
|
36,094
|
|||||||||||||||
|
Research and development expenses
|
9,702
|
12,663
|
13,915
|
14,820
|
15,075
|
|||||||||||||||
|
Sales and marketing expenses
|
5,651
|
6,423
|
6,722
|
6,642
|
6,647
|
|||||||||||||||
|
General and administrative expenses
|
3,611
|
3,969
|
4,507
|
3,943
|
4,159
|
|||||||||||||||
|
Contingent consideration expense (benefit)
|
(3,090
|
)
|
(334
|
)
|
(4,642
|
)
|
-
|
-
|
||||||||||||
|
Total operating expenses
|
15,874
|
22,721
|
20,502
|
25,405
|
25,881
|
|||||||||||||||
|
Operating income
|
18,205
|
15,830
|
25,426
|
16,651
|
10,213
|
|||||||||||||||
|
Financial income, net
|
220
|
35
|
156
|
923
|
1,646
|
|||||||||||||||
|
Income before income taxes
|
18,425
|
15,865
|
25,582
|
17,574
|
11,859
|
|||||||||||||||
|
Income tax expenses
|
1,905
|
2,728
|
3,868
|
2,937
|
1,623
|
|||||||||||||||
|
Net income
(1)
|
16,520
|
13,137
|
21,714
|
14,637
|
10,236
|
|||||||||||||||
|
Net income per share
|
||||||||||||||||||||
|
Basic income per ordinary share
|
$
|
2.273
|
$
|
1.789
|
$
|
2.912
|
$ |
1.938
|
$ |
1.361
|
||||||||||
|
Diluted income per ordinary share
|
$
|
2.242
|
$
|
1.767
|
$
|
2.856
|
$ |
1.912
|
$ |
1.352
|
||||||||||
|
Weighted average number of ordinary shares used to compute basic income per share (in thousands)
|
7,269
|
7,344
|
7,456
|
7,552
|
7,520
|
|||||||||||||||
|
Weighted average number of ordinary shares used to compute diluted income per share (in thousands)
|
7,368
|
7,435
|
7,602
|
7,657
|
7,573
|
|||||||||||||||
|
2015
|
2016
|
2017
|
2018
|
2019
|
||||||||||||||||
|
Total assets
|
$
|
139,998
|
$
|
146,437
|
$
|
162,614
|
$
|
182,301
|
$
|
195,063
|
||||||||||
|
Total current liabilities
|
$
|
19,814
|
$
|
17,964
|
$
|
19,049
|
$
|
21,540
|
$
|
26,332
|
||||||||||
|
Long-term liability
|
$
|
7,350
|
$
|
7,081
|
$
|
2,765
|
$
|
2,612
|
$
|
5,808
|
||||||||||
|
Shareholders' equity
|
$
|
112,834
|
$
|
121,392
|
$
|
140,800
|
$
|
158,149
|
$
|
162,923
|
||||||||||
|
Capital stock
|
$
|
21
|
$
|
22
|
$
|
22
|
$
|
22
|
$
|
22
|
||||||||||
|
Number of ordinary shares issued
(1)
|
7,299,315
|
7,396,584
|
7,564,502
|
7,574,176
|
7,618,676
|
|||||||||||||||
|
NIS per U.S. $
|
||||||||||||||||
|
Year Ended December 31,
|
High
|
Low
|
Average
|
Period End
|
||||||||||||
|
2019
|
3.746
|
3.455
|
3.565
|
3.456
|
||||||||||||
|
2018
|
3.781
|
3.388
|
3.597
|
3.748
|
||||||||||||
|
2017
|
3.860
|
3.467
|
3.600
|
3.467
|
||||||||||||
|
2016
|
3.983
|
3.746
|
3.841
|
3.845
|
||||||||||||
|
2015
|
4.053
|
3.761
|
3.887
|
3.902
|
||||||||||||
|
|
NIS per U.S. $
|
|||||||||||||||
|
Month
|
High
|
Low
|
Average
|
Period End
|
||||||||||||
|
March 2020
|
3.862
|
3.460
|
3.618
|
3.565
|
||||||||||||
|
February 2020
|
3.467
|
3.416
|
3.434
|
3.467
|
||||||||||||
|
January 2020
|
3.475
|
3.448
|
3.460
|
3.448
|
||||||||||||
|
December 2019
|
3.501
|
3.456
|
3.475
|
3.456
|
||||||||||||
|
November 2019
|
3.522
|
3.455
|
3.483
|
3.476
|
||||||||||||
|
October 2019
|
3.545
|
3.481
|
3.519
|
3.529
|
||||||||||||
| • |
As any number of the members of our workforce, including key employees, may be infected and/or subject to quarantine periods and may be unable to perform their duties and our offices and factories may be forced to operate with a
reduced workforce and/or be forced to close under the temporary emergency regulations. This may lead to ineffective control over our business and a lower work efficiency, productivity, manufacturing and financial performance;
|
| • |
A reduced workforce, lack of international travel, and no face to face meetings may adversely affect our operations, including our R&D efforts, marketing and sales activities, the materialization of existing Design Wins, and
the achievement of new Design Wins;
|
| • |
We rely on third-party suppliers and manufacturers for many of our products. This outbreak has resulted in the extended shutdown of certain businesses globally, which may in turn result in disruptions or delays to our supply chain.
These may include disruptions from the temporary closure of third-party supplier and manufacturer facilities, interruptions in product supply or restrictions on the export or shipment of our products. Any disruption of our suppliers
and their contract manufacturers will likely impact our sales and operating results and Design Win related activities;
|
| • |
Due to the impact of Covid-19 on flights and airlines, which reduced air transportation dramatically, we may be significantly limited, or it may be impossible, for us to ship our products to our customers and/or receive components
and other bill of material parts from our suppliers;
|
| • |
We may experience difficulties in collecting amounts due from customers, including major customers, due to a downturn in their financial condition;
|
| • |
Due to the pandemic, significant number of our employees have moved to work from their homes and remotely access our IT networks. Such remote working mode creates the risk of attacking the end-point user stations, connection
channels and gateways. These potential breaches of our security measures may harm our business;
|
| • |
In the past, following periods of market volatility, shareholders have often instituted securities class action litigation. If we were involved in securities litigation, it could have a substantial cost and divert resources and
attention of management from our business, even if we are successful.
|
| • |
Substantial research and development and business development expenditures, which could divert funds from other corporate uses and/or have a significant negative effect on our short-term results;
|
| • |
Diversion of management's attention from our core business; and
|
| • |
Entrance into markets in which we have little or no experience.
|
| • |
Post-merger integration problems resulting from the combination of any acquired operations with our own operations or from the combination of two or more operations into a new merged entity;
|
| • |
Diversion of management's attention from our core business;
|
| • |
Substantial expenditures, which could divert funds from other corporate uses;
|
| • |
Entering markets in which we have little or no experience; and
|
| • |
Loss of key employees of the acquired operations.
|
| (i) |
Server network interface cards (Server Adapters);
|
| (ii) |
Smart Cards: Intelligent and/or programmable cards, with features such as encryption, acceleration, data compression, redirection and switching, packet processing, time stamping, packet capture solutions, ultra-low latency solutions,
other offloading features; and
|
| (iii) |
Stand-alone Products: Customer-Premises Equipment, including virtualized Customer-Premises Equipment (vCPE) and universal Customer-Premises Equipment (uCPE) (together, "CPE"), edge devices for SD-WAN and NFV deployments (together
with the CPE, "EDGE"), Networking Targeted Appliances, Bypass Switches and Intelligent Bypass Switches.
|
| (i) |
Providers of Network appliances, including WAN Optimization and SD-WAN, Internet Security, Cyber Security, Application Delivery, Traffic Management, Network Monitoring and Analytics, and High Frequency Trading (HFT) for the financial
service market and other mission-critical sectors;
|
| (ii) |
Telcos / Carriers / service providers deploying white boxes CPEs for SD-WAN and NFV;
|
| (iii) |
The "Cloud";
|
| (iv) |
Servers;
|
| (v) |
Data Storage including Big Data; and
|
| (vi) |
IoT.
|
| • |
We approach a potential customer or are approached by such customer.
|
| • |
If the potential customer shows interest in the products and we believe that achievement of a business relationship with the potential customer is possible, we ship products for such potential customer's evaluation.
|
| • |
During the evaluation process the potential customer receives a few units of the relevant product for initial basic testing. If the evaluation process is successful, we ship products for qualification.
|
| • |
During the qualification process the potential customer usually purchases a larger amount of our products for more specific testing, which may include certain adaptations of our products to its needs.
|
| • |
If the qualification process is successful, we enter into negotiations regarding the terms of a business relationship.
|
| • |
In some cases, typically with the larger customers and with respect to Smart Cards, the evaluation and qualification process may take 12 months or more.
|
| • |
Silicom Connectivity Solutions, Inc. – a private company incorporated in the United States; and
|
| • |
Silicom Denmark (Fiberblaze A/S) – a private company incorporated in Denmark. On December 10, 2014, we entered into the Fiberblaze SPA for the purchase of the entire holdings in Fiberblaze, pursuant to which we became its sole
shareholder. As part of the Fiberblaze SPA, we have also purchased Fiberblaze US LLC, a private company incorporated in the United States, being a 100% owned subsidiary of Fiberblaze. In October 2016, we commenced a voluntary
liquidation process for the liquidation of Fiberblaze US LLC, which was completed in August 2017. In 2017, we changed the name of the company from Fiberblaze A/S to the company's current name – Silicom Denmark (Fiberblaze A/S) and all
the rights related to the company's previous name remained ours. See "Item 10 – Additional Information – C. "Material Contracts" for additional information on the Fiberblaze SPA.
|
| Year Ended December 31, |
2017
|
2018
|
2019
|
|||||||||
|
Sales
|
100
|
%
|
100
|
%
|
100
|
%
|
||||||
|
Cost of sales
|
63.5
|
68.6
|
65.7
|
|||||||||
|
Gross profit
|
36.5
|
31.4
|
34.3
|
|||||||||
|
Research and development expenses
|
11.1
|
11.1
|
14.3
|
|||||||||
|
Sales and marketing expenses
|
5.3
|
5.0
|
6.3
|
|||||||||
|
General and administrative expenses
|
3.6
|
2.9
|
4.0
|
|||||||||
|
Contingent consideration expense (benefit)
|
(3.7
|
)
|
-
|
-
|
||||||||
|
Operating Income
|
20.2
|
12.4
|
9.7
|
|||||||||
|
Financial income, net
|
0.2
|
0.7
|
1.6
|
|||||||||
|
Income before income taxes
|
20.4
|
13.1
|
11.3
|
|||||||||
|
Income tax expenses
|
3.1
|
2.2
|
1.6
|
|||||||||
|
Net Income
|
17.3
|
10.9
|
9.7
|
|||||||||
|
Payments due by period
|
||||||||||||||||||||
|
Contractual Obligations
|
Total
|
Less than 1 year
|
1-3 years
|
3-5 years
|
More than 5 years
|
|||||||||||||||
|
Operating Leases
|
4,533
|
1,482
|
1,684
|
1,161
|
206
|
|||||||||||||||
|
Purchase Obligations
|
15,043
|
15,042
|
1
|
|||||||||||||||||
|
Total
|
19,576
|
16,524
|
1,685
|
1,161
|
206
|
|||||||||||||||
|
Name
|
Age
|
Position with Company
|
|
Avi Eizenman
(1)
|
62
|
Active Chairman of the Board
|
|
Shaike Orbach
(2)
|
68
|
President, Chief Executive Officer, Director
|
|
Ayelet Aya Hayak
(3)
|
50
|
External Director
|
|
Ilan Erez
(3)
|
52
|
External Director
|
|
Eli Doron
(4)
|
67
|
Director
|
|
Eran Gilad
|
52
|
Chief Financial Officer and Company Secretary
|
| (1) |
Was re-elected for an additional three-year term, commencing as of June 5, 2019.
|
| (2) |
Was re-elected for an additional three-year term, commencing as of June 5, 2017.
|
| (3) |
Was re-elected for an additional three-year term, commencing as of July 1, 2019.
|
| (4) |
Was re-elected for an additional three-year term, commencing as of June 12, 2018.
|
|
Name and Position
|
Salary and Benefits(1)
|
Cash Bonus(2)
|
Equity-based Compensation(3)
|
Total
|
||||||||||||
|
Avi Eizenman –
Active Chairman
|
595,803
|
129,798
|
369,257
|
1,094,858
|
||||||||||||
|
Yeshayahu ('Shaike') Orbach – CEO and President
|
403,137
|
129,798
|
369,257
|
902,192
|
||||||||||||
|
Elad Blatt – Chief Strategy and Business Development Officer
|
281,310
|
48,689
|
77,855
|
407,854
|
||||||||||||
|
David Hendel – VP Research and Development
|
241,555
|
26,174
|
77,855
|
345,584
|
||||||||||||
|
Eran Gilad – CFO and Company Secretary
|
237,804
|
26,174
|
77,855
|
341,833
|
||||||||||||
| (1) |
"
Salary and Benefits
" include annual salary or service fees paid, payments to the National Insurance Institute, manager's insurance and pension funds, severance, advanced education funds,
basic health insurance, vacation pay, recuperation pay, tax gross-up payments, automobile-related expenses, telephone expenses and benefits and perquisites as mandated by Israeli or applicable law.
|
| (2) |
"
Cash Bonus
" includes bonus payments as recorded in our financial statements for the year ended December 31, 2019.
|
| (3) |
"
Equity-based Compensation
" includes the expense recorded in our financial statements for the year ended December 31, 2019 with respect to equity-based compensation granted to the executive
officers detailed above.
|
| • |
An employment relationship;
|
| • |
A business or professional relationship maintained on a regular basis;
|
| • |
Control; and
|
| • |
Service as an office holder.
|
| • |
the majority includes at least a majority of the shares held by non-controlling and disinterested shareholders who are present and voting at the meeting; or
|
| • |
the total number of shares held by non-controlling and disinterested shareholders that voted against the election of the director does not exceed two percent of the aggregate voting rights in the company.
|
| • |
The chairman of the board of directors;
|
| • |
Any director employed by or otherwise providing services to the company or to the "controlling shareholder" or entity under such controlling shareholder's control;
|
| • |
Any director who derives his salary primarily from a controlling shareholder;
|
| • |
A "controlling shareholder"; or
|
| • |
Any relative of a "controlling shareholder".
|
| • |
The chairman of the board of directors;
|
| • |
Any director employed by or otherwise providing services to the company or to the controlling shareholder or entity under such controlling shareholder's control;
|
| • |
Any director who derives his salary primarily from a "controlling shareholder;"
|
| • |
A "controlling shareholder"; or
|
| • |
Any relative of a "controlling shareholder".
|
| 1. |
To recommend to the Board of Directors as to a compensation policy for office holders of the company, as well as to recommend, once every three years to extend the compensation policy subject to receipt of the required corporate
approvals;
|
| 2. |
To recommend to the Board of Directors as to any updates to the compensation policy which may be required;
|
| 3. |
To review the implementation of the compensation policy by the company;
|
| 4. |
To approve transactions relating to terms of office and employment of certain company office holders, which require the approval of the compensation committee pursuant to the Companies Law; and
|
| 5. |
To exempt, under certain circumstances, a transaction relating to terms of office and employment from the requirement of approval of the shareholders meeting.
|
| a. |
Advancement of the goals of the company, its working plan and its long term policy;
|
| b. |
The creation of proper incentives for the office holders while taking into consideration, inter alia, the company's risk management policies;
|
| c. |
The company's size and nature of its operations;
|
| d. |
The contributions of the relevant office holders in achieving the goals of the company and profit in the long term in light of their positions;
|
| e. |
The education, skills, expertise and achievements of the relevant office holders;
|
| f. |
The role of the office holders, areas of their responsibilities and previous agreements with them;
|
| g. |
The correlation of the proposed compensation with the compensation of other employees of the company, and the effect of such differences in compensation on the employment relations in the company; and
|
| h. |
The long term performance of the office holder.
|
| (i) |
the majority of the votes includes at least a majority of all the votes of shareholders who are not controlling shareholders of the company or who do not have a personal interest in the compensation policy and participating in the
vote; abstentions shall not be included in the total of the votes of the aforesaid shareholders; or
|
| (ii) |
the total of opposing votes from among the shareholders described in Sub-section (i) above does not exceed 2% of all the voting rights in the company.
|
|
As of December 31,
|
2017
|
2018
|
2019
|
|||||||||
|
Total Employees
|
255
|
270
|
260
|
|||||||||
|
Marketing, Sales, Customer Services
|
23
|
24
|
25
|
|||||||||
|
Research & Development
|
93
|
106
|
106
|
|||||||||
|
Manufacturing
|
123
|
125
|
110
|
|||||||||
|
Corporate Operations and Administration
|
16
|
15
|
19
|
|||||||||
|
Name
|
Number of Shares and Options Owned1
|
Percent of Outstanding Shares
|
||||||
|
Avi Eizenmann
|
305,750
|
4.13
|
%
|
|||||
|
Shaike Orbach
|
*
|
*
|
||||||
|
Eli Doron
|
*
|
*
|
||||||
|
Ayelet Aya Hayak
|
*
|
*
|
||||||
|
Ilan Erez
|
*
|
*
|
||||||
|
Eran Gilad
|
*
|
*
|
||||||
|
All directors and office holders as a group
|
372,248
|
5.03
|
%
|
|||||
| * |
Denotes ownership of less than 1% of the outstanding shares.
|
| (1) |
The table above includes the number of shares and options that are exercisable within 60 days of March 31, 2020. Ordinary shares subject to these options are deemed beneficially owned for the purpose of computing the ownership
percentage of the person or group holding these options, but are not deemed outstanding for purposes of computing the ownership percentage of any other person. Except where otherwise indicated, and subject to applicable community
property laws, based on information furnished to us by such owners or otherwise disclosed in any public filings, to our knowledge, the persons and entities named in the table have sole voting and dispositive power with respect to all
shares shown as beneficially owned by them.
|
|
|
Number of
Shares and Options
Owned
(1)
|
Percentage
of Outstanding
Shares
|
||||||
|
Wellington Management Group LLP
(2)
|
1,003,394
|
13.87
|
%
|
|||||
|
Wellington Trust Company, NA
(3)
|
930,035
|
12.86
|
%
|
|||||
|
Wellington Trust Company, National Association Multiple Common Trust Funds Trust, Micro Cap Equity Portfolio
(4)
|
425,033
|
5.88
|
%
|
|||||
|
Zohar Zisapel
(5)
|
723,706
|
10.01
|
%
|
|||||
|
Ibex Investors LLC/ Justin B. Borus, Ibex Israel Fund LLLP/Ibex GP LLC/Ibex Investment Holdings LLC/Ibex Investment Holdings II LLC
(6)
|
530,700
|
7.34
|
%
|
|||||
|
Dov Yelin/Yair Lapidot/Yelin Lapidot Holdings Management Ltd./ Yelin Lapidot Mutual Funds Management Ltd.
(7)
|
470,091
|
6.50
|
%
|
|||||
|
|
(1) |
The table above includes the number of shares and options that are exercisable within 60 days of March 31, 2020. Ordinary shares subject to these options are deemed beneficially owned for the purpose of computing the ownership
percentage of the person or group holding these options, but are not deemed outstanding for purposes of computing the ownership percentage of any other person. Except where otherwise indicated, and subject to applicable community
property laws, based on information furnished to us by such owners or otherwise disclosed in any public filings, to our knowledge, the persons and entities named in the table have sole voting and dispositive power with respect to all
shares shown as beneficially owned by them. All the information detailed in this table is as set forth in major shareholders' public filings, unless stated otherwise.
|
|
|
(2) |
As reported on the Schedule 13G/A filed by Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP and Wellington Management Company LLP with the SEC on January 28, 2020. The
securities as to which the Schedule was filed are owned of record by clients of one or more investment advisers, which are directly or indirectly owned by Wellington Management Group LLP.
|
|
|
(3) |
As reported on Schedule 13G filed by Wellington Trust Company, NA with the SEC on January 29, 2020. The securities as to which the Schedule was filed by Wellington Trust Company, NA, in its capacity as investment adviser, are owned
of record by clients of Wellington Trust Company, NA. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have
such right or power with respect to more than five percent of this class of securities.
|
|
|
(4) |
As reported on Schedule 13G filed by Wellington Trust Company, National Association Multiple Common Trust Funds Trust, Micro Cap Equity Portfolio with the SEC on January 30, 2020.
|
|
|
(5) |
As reported on Schedule 13D/A filed by Zohar Zisapel with the SEC on January 16, 2019.
|
|
|
(6) |
As reported on Schedule 13G filed by Ibex Investors LLC (the "Investment Manager"), Justin B. Borus, Ibex Israel Fund LLLP (the "Fund"), Ibex GP LLC (the "General Partner"), Ibex Investment Holdings LLC
("IM Holdings") and Ibex Investment Holdings II LLC ("GP Holdings") with the SEC on January 24, 2020, the Fund is a private investment vehicle. The Fund directly beneficially owns the Company's ordinary shares detailed in the
Schedule. The Investment Manager is the investment manager of the Fund. IM Holdings is the sole member of the Investment Manager. The General Partner is the general partner of the Fund. GP Holdings is the sole member of the General
Partner. Justin B. Borus is the manager of the Investment Manager, IM Holdings, the General Partner and GP Holdings. Justin B. Borus, the Investment Manager, IM Holdings, the General Partner and GP Holdings may be deemed to
beneficially own the Company's ordinary shares reported in the Schedule, directly beneficially owned by the Fund. Each of the reporting person detailed in the Schedule disclaimed beneficial ownership with respect to any shares other
than the shares directly beneficially owned by such reporting person.
|
|
|
(7) |
As reported on the Schedules 13G/A filed by each of Dov Yelin ("Yelin"), Yair Lapidot ("Lapidot"), Yelin Lapidot Holdings Management Ltd. ("Yelin Lapidot Holdings"), and Yelin Lapidot Mutual Funds
Management Ltd. (collectively, "Yelin Lapidot") with the SEC on January 27, 2019, all ordinary shares of the Company are beneficially owned by provident funds managed by Yelin Lapidot Provident Funds Management Ltd. and/or mutual
funds managed by Yelin Lapidot Mutual Funds Management Ltd. (the "Subsidiaries"), each a wholly-owned subsidiary of Yelin Lapidot Holdings. Messrs. Yelin and Lapidot each own 24.38% of the share capital and 25.004% of the voting
rights of Yelin Lapidot Holdings, and are responsible for the day-to-day management of Yelin Lapidot Holdings. The Subsidiaries operate under independent management and make their own independent voting and investment decisions. Any
economic interest or beneficial ownership in any of the securities covered by the Schedule is held for the benefit of the members of the provident funds or mutual funds, as the case may be. According to the Schedule, the Schedule
shall not be construed as an admission by Messrs. Yelin and Lapidot, Yelin Lapidot Holdings or the Subsidiaries that he or it is the beneficial owner of any of the securities covered by the Schedule, and each of Messrs. Yelin and
Lapidot, Yelin Lapidot Holdings, and the Subsidiaries disclaims beneficial ownership of any such securities.
|
|
PERIOD
|
LOW
|
HIGH
|
||||||
|
LAST 6 CALENDAR MONTHS
|
||||||||
|
March 2020
|
20.93
|
31.49
|
||||||
|
February 2020
|
29.00
|
35.79
|
||||||
|
January 2020
|
32.75
|
37.60
|
||||||
|
December 2019
|
31.51
|
33.78
|
||||||
|
November 2019
|
30.19
|
34.20
|
||||||
|
October 2019
|
29.30
|
35.02
|
||||||
|
FINANCIAL QUARTERS DURING THE PAST TWO YEARS
|
||||||||
|
First Quarter 2020
|
20.93
|
37.60
|
||||||
|
Fourth Quarter 2019
|
29.30
|
35.02
|
||||||
|
Third Quarter 2019
|
28.59
|
34.03
|
||||||
|
Second Quarter 2019
|
28.63
|
39.70
|
||||||
|
First Quarter 2019
|
30.58
|
40.36
|
||||||
|
Fourth Quarter 2018
|
32.10
|
45.50
|
||||||
|
Third Quarter 2018
|
36.59
|
44.68
|
||||||
|
Second Quarter 2018
|
33.12
|
43.50
|
||||||
|
FIVE MOST RECENT FULL FINANCIAL YEARS
|
||||||||
|
2019
|
28.59
|
40.36
|
||||||
|
2018
|
32.00
|
77.95
|
||||||
|
2017
|
34.86
|
77.05
|
||||||
|
2016
|
25.48
|
44.00
|
||||||
|
2015
|
24.86
|
48.43
|
||||||
|
PERIOD
|
LOW
|
HIGH
|
||||||
|
FIVE MOST RECENT FULL FINANCIAL YEARS
|
||||||||
|
2015
|
96.01
|
189.60
|
||||||
| • |
Appointment or termination of our auditors;
|
| • |
Appointment and dismissal of external directors, unless the company elects to opt-in to the exemptions promulgated under the Amendment to the Relief Regulations as detailed above, under which there is no requirement to appoint
external directors;
|
| • |
Approval of interested party acts and transactions requiring general meeting approval as provided in Sections 255 and 268 to 275 of the Companies Law;
|
| • |
A merger as provided in Section 320(a) of the Companies Law;
|
| • |
The exercise of the powers of the board of directors, if the board of directors is unable to exercise its powers and the exercise of any of its powers is vital for our proper management, as provided in Section 52(a) of the Companies
Law;
|
| • |
Amendments to our Articles; and
|
| • |
Approval of an increase or decrease of the registered share capital.
|
| • |
All of the directors are permitted to vote on the matter and attend the meeting in which the matter is considered; and
|
| • |
The matter requires approval of the shareholders at a general meeting.
|
| 1. |
A private placement that meets all of the following conditions:
|
|
|
• |
The private placement will increase the relative holdings of a shareholder that holds five percent or more of the company's outstanding share capital, assuming the exercise of all of the securities convertible into shares held by
that person, or that will cause any person to become, as a result of the issuance, a holder of more than five percent of the company's outstanding share capital.
|
|
|
• |
20 percent or more of the voting rights in the company prior to such issuance are being offered.
|
|
|
• |
All or part of the consideration for the offering is not cash or registered securities, or the private placement is not being offered at market terms.
|
| 2. |
A private placement which results in anyone becoming a "controlling shareholder" of the public company.
|
| • |
Any amendment to the articles of association;
|
| • |
An increase of the company's authorized share capital;
|
| • |
A merger; or
|
| • |
Approval of interested party acts and transactions that require general meeting approval as provided in Sections 255 and 268 to 275 of the Companies Law.
|
| • |
Distribution of annual and quarterly reports to shareholders
– Under Israeli law we are not required to distribute annual and quarterly reports directly to shareholders and the
generally accepted business practice in Israel is not to distribute such reports to shareholders. We do however make our audited financial statements available to our shareholders prior to our annual general meeting and furnish our
quarterly and annual financial results with the SEC on Form 6-K.
|
| • |
Independence, Nomination and Compensation of Directors
– A majority of our board of directors may not necessarily be comprised of independent
directors as defined in NASDAQ Listing Rule 5605(a)(2). Our board of directors contains two external directors in accordance with the provisions of the Companies Law. Israeli law does not require, nor do our external directors conduct,
regularly scheduled meetings at which only they are present. In addition, with the exception of our external directors, our directors are elected to our board of directors in accordance with the provisions set forth in our Amended and
Restated Articles of Association, as approved by our shareholders on the Annual General Meeting which took place on June 8, 2016. According to our Amended and Restated Articles of Association, directors are divided into three groups,
Group A, Group B and Group C. Each group is brought for re-election once every three years, on a rotating basis, such that at each annual general meeting of the shareholders a given group of directors is brought for election, to serve
on a continuous basis for a three-year term, until the third annual general meeting following the meeting on which such group was elected for service and until their respective successors are duly elected, at which point their term in
office shall expire. At each annual general meeting, the annual general meeting shall be entitled to elect directors to replace the directors whose three-year term in office has expired, and so on ad infinitum, so that each year, the
term in office of one group of directors shall expire. The nominations for director which are presented to our shareholders are generally made by our board of directors. One or more shareholders of a company holding at least one percent
of the voting power of the company may nominate a currently serving external director for an additional three-year term. Israeli law does not require the adoption of, and our board has not adopted, a formal written charter or board
resolution addressing the nomination process and related matters. Compensation of our directors and other office holders of the Company is determined in accordance with Israeli law.
|
| • |
Audit Committee
– Our audit committee does not meet with all the requirements of NASDAQ Listing Rule 5605. We are of the opinion that the members of our audit committee comply with the
requirements of NASDAQ Listing Rule 5605(c)(3) and Rule 10A-3(b) of the general rules and regulations promulgated under the Securities Act of 1933 and all requirements under Israeli law. Our audit committee has not adopted a formal
written audit committee charter specifying the items enumerated in NASDAQ Listing Rule 5605(c)(1).
|
| • |
Compensation Committee
– We follow the provisions of the Companies Law with respect to matters in connection with the composition and
responsibilities of our compensation committee, office holder compensation, and any required approval by the shareholders of such compensation. Israeli law, and our amended and restated Articles, do not require that a compensation
committee composed solely of independent members of our board of directors determine (or recommend to the board of directors for determination) an executive officer's compensation, as required under NASDAQ's listing standards related to
compensation committee independence and responsibilities; nor do they require that the Company adopt and file a compensation committee charter. Instead, our compensation committee has been established and conducts itself in accordance
with provisions governing the composition of and the responsibilities of a compensation committee as set forth in the Companies Law. Furthermore, the compensation of office holders is determined and approved by our compensation
committee and our board of directors, and in certain circumstances by our shareholders, either in consistency with our previously approved Executive Compensation Policy or, in special circumstances in deviation therefrom, taking into
account certain considerations set forth in the Companies Law. The requirements for shareholder approval of any office holder compensation, and the relevant majority or special majority for such approval, are all as set forth in the
Companies Law. Thus, we will seek shareholder approval for all corporate actions with respect to office holder compensation requiring such approval under the requirements of the Companies Law, including seeking prior approval of the
shareholders for the Executive Compensation Policy and for certain office holder compensation, rather than seeking approval for such corporate actions in accordance with NASDAQ Listing Rules.
|
| • |
Quorum
– Under Israeli law a company is entitled to determine in its articles of association the number of shareholders and percentage of holdings required for a quorum at a
shareholders meeting. Our Articles provide that a quorum of two or more shareholders, present in person or by proxy, holding shares conferring in the aggregate more than thirty three and a third (33 1/3 %) percent of the voting power of
the Company is required for commencement of business at a general meeting.
|
| • |
Approval of Related Party Transactions
– All related party transactions are approved in accordance with the requirements and procedures for approval of interested party acts and
transactions, set forth in Sections 268 to 275 of the Companies Law.
|
| • |
Shareholder Approval
– We seek shareholder approval for all corporate action requiring such approval, in accordance with the requirements of the Companies Law.
|
| • |
Equity Compensation Plans
– We do not necessarily seek shareholder approval for the establishment of, and amendments to, stock option or equity compensation plans (as set forth in
NASDAQ Listing Rule 5635(c)), as such matters are not subject to shareholder approval under Israeli law. We will attempt to seek shareholder approval for our stock option or equity compensation plans (and the relevant annexes thereto)
to the extent required in order to ensure they are tax qualified for our employees in the United States. However, even if such approval is not received, then the stock option or equity compensation plans will continue to be in effect,
but the Company will be unable to grant options to its U.S. employees that qualify as Incentive Stock Options for U.S. federal tax purpose. Our stock option or other equity compensation plans are also available to our non-U.S.
employees, and provide features necessary to comply with applicable non-U.S. tax laws.
|
| (a) |
Amortization of expenses incurred in connection with certain public securities issuances over a three-year period; and
|
| (b) |
Accelerated depreciation rates on know-how, patents and/or right to use a patent or certain other intangible property rights.
|
|
2019
|
2018
|
|||||||
|
Audit Fees
(1)
|
$
|
120,000
|
$
|
120,000
|
||||
|
Audit-Related Fees
(2)
|
-
|
-
|
||||||
|
Tax Fees
(3)
|
$
|
9,234
|
$
|
10,000
|
||||
| (1) |
Audit fees consist of fees for professional services rendered for the audit of the Company's annual consolidated financial statements and services normally provided by the independent auditor in connection with statutory and
regulatory filings or engagements.
|
| (2) |
Audit-Related Fees consist of accounting consultation and consultation on financial accounting standards, not arising as part of the audit.
|
| (3) |
Tax Fees are the aggregate fees billed for professional services rendered for tax compliance, transfer pricing studies, and tax advice other than in connection with the Audit. Tax compliance involves audit of original and amended tax
returns, tax planning and tax advice.
|
|
Period
|
Total Number of Shares Purchased
|
Average Price Paid per Share (US$)
|
Total Number of Shares Purchased as Part of Publicly Announced Plan
|
Approximate Dollar Value that May Yet Be Purchased Under the Plan (US$)
|
||||||||||||
|
May 22, 2019 - May 31, 2019
|
12,027
|
30.074
|
12,027
|
14,638,294
|
||||||||||||
|
June 1, 2019 - June 30, 2019
|
28,098
|
30.141
|
40,125
|
13,791,381
|
||||||||||||
|
July 1, 2019 - July 31, 2019
|
37,934
|
30.888
|
78,059
|
12,619,661
|
||||||||||||
|
August 1, 2019 - August 31, 2019
|
37,190
|
30.902
|
115,249
|
11,470,400
|
||||||||||||
|
September 1, 2019 - September 30, 2019
|
29,406
|
32.263
|
144,655
|
10,521,675
|
||||||||||||
|
October 1, 2019 - October 31, 2019
|
37,707
|
31.744
|
182,362
|
9,324,699
|
||||||||||||
|
November 1, 2019 - November 30, 2019
|
40,838
|
32.378
|
223,200
|
8,002,442
|
||||||||||||
|
December 1, 2019 - December 31, 2019
|
29,188
|
32.710
|
252,388
|
7,047,695
|
||||||||||||
|
January 1, 2020 - January 31, 2020
|
40,164
|
35.631
|
292,552
|
5,616,603
|
||||||||||||
|
February 1, 2020 - February 29, 2020
|
43,176
|
33.619
|
335,728
|
4,165,059
|
||||||||||||
|
March 1, 2020 - March 30, 2020
|
75,070
|
26.235
|
410,798
|
2,195,622
|
||||||||||||
| • |
We are not required to distribute annual and quarterly reports directly to shareholders, but we do make our audited financial statements available to our shareholders prior to our annual general meeting and furnish our quarterly and
annual financial results with the SEC on Form 6-K;
|
| • |
A majority of our board of directors may not necessarily be comprised of independent directors as defined in the NASDAQ Listing Rules, but our board of directors contains two external directors in accordance with the Companies Law.
Israeli law does not require, nor do our external directors conduct, regularly scheduled meetings at which only they are present. In addition, with the exception of our external directors, in addition, with the exception of our external
directors, our directors are elected to our board of directors in accordance with the new directors voting mechanism approved by our shareholders on the Annual General Meeting which took place on June 8, 2016. According to said
directors voting mechanism, directors are divided into three groups, Group A, Group B and Group C. Each group is brought for re-election once every three years, on a rotating basis, such that at each annual general meeting of the
shareholders a given group of directors is brought for election, to serve on a continuous basis for a three-year term, until the third annual general meeting following the meeting on which such group was elected for service and until
their respective successors are duly elected, at which point their term in office shall expire. At each annual general meeting, the annual general meeting shall be entitled to elect directors to replace the directors whose three-year
term in office has expired, and so on ad infinitum, so that each year, the term in office of one group of directors shall expire. The nominations for director which are presented to our shareholders are generally made by our board of
directors. Pursuant to the Companies Law, one or more shareholders of a company holding at least one percent of the voting power of the company may nominate a currently serving external director for an additional three-year term.
Israeli law does not require the adoption of, and our board has not adopted, a formal written charter or board resolution addressing the nomination process and related matters. Compensation of our directors and other office holders of
the Company is determined in accordance with Israeli law;
|
| • |
Our audit committee has not adopted a formal written audit committee charter specifying the items enumerated in NASDAQ Listing Rule 5605(c)(1). We believe that the members of our audit committee comply with the requirements of the
Israeli law, as well as NASDAQ Listing Rule 5605(c)(3) and Rule 10A-3(b) of the general rules and regulations promulgated under the Securities Act of 1933. For a detailed discussion please refer to "Item 6 – Directors, Senior Management
and Employees – Audit Committee";
|
| • |
As opposed to NASDAQ Listing Rule 5620(c)(3), which sets forth a minimum quorum for a shareholders meeting, under Israeli law a company is entitled to determine in its articles of association the number of shareholders and percentage
of holdings required for a quorum at a shareholders meeting. Our current Articles provide that a quorum of two or more shareholders, present in person or by proxy, holding shares conferring in the aggregate more than thirty three and a
third (33 1/3 %) percent of the voting power of the Company is required;
|
| • |
All related party transactions are approved in accordance with the requirements and procedures for approval of interested party acts and transactions set forth in the Companies Law, and are not subject to the review process set forth
in NASDAQ Listing Rule 5630. For a detailed discussion please refer to "Item 10 – Additional Information – the Companies Law";
|
| • |
We seek shareholder approval for all corporate action requiring such approval in accordance with the requirements of the Companies Law rather than under the requirements of the NASDAQ Marketplace Rules, including (but not limited to)
the appointment or termination of auditors, appointment and dismissal of directors, approval of interested party acts and transactions requiring general meeting approval as discussed above and a merger;
|
| • |
We follow the provisions of the Companies Law with respect to matters in connection with the composition and responsibilities of our compensation committee, office holder compensation, and any required approval by the shareholders of
such compensation. Israeli law, and our amended and restated Articles, do not require that a compensation committee composed solely of independent members of our board of directors determine (or recommend to the board of directors for
determination) an executive officer's compensation, as required under NASDAQ listing standards related to compensation committee independence and responsibilities; nor do they require that the Company adopt and file a compensation
committee charter. Instead, our compensation committee has been established and conducts itself in accordance with provisions governing the composition of and the responsibilities of a compensation committee as set forth in the
Companies Law. Furthermore, the compensation of office holders is determined and approved by our compensation committee and our board of directors, and in certain circumstances by our shareholders, either in consistency with our
previously approved Executive Compensation Policy or, in special circumstances in deviation therefrom, taking into account certain considerations set forth in the Companies Law. The requirements for approval by the shareholders for any
office holder compensation, and the relevant majority or special majority for such approval, are all as set forth in the Companies Law. Thus, we will seek shareholder approval for all corporate actions with respect to office holder
compensation requiring such approval under the requirements of the Companies Law, including seeking prior approval of the shareholders for the Executive Compensation Policy and for certain office holder compensation, rather than seeking
approval for such corporate actions in accordance with NASDAQ Listing Rules; and
|
| • |
We do not necessarily seek shareholder approval for the establishment of, and amendments to, stock option or equity compensation plans (as set forth in NASDAQ Listing Rule 5635(c)), as such matters are not subject to shareholder
approval under Israeli law. We will attempt to seek shareholder approval for our stock option or equity compensation plans (and the relevant annexes thereto) to the extent required in order to ensure they are tax qualified for our
employees in the United States. However, if such approval is not received, then the stock option or equity compensation plans will continue to be in effect, but the Company will be unable to grant options to its U.S. employees that
qualify as Incentive Stock Options for U.S. federal tax purpose. Our stock option or other equity compensation plans are also available to our non-U.S. employees, and provide features necessary to comply with applicable non-U.S. tax
laws.
|
| 4.6 |
Lease between Silicom Connectivity Solutions, Inc. and RAD Data Communications Inc., for space in Mahwah, New Jersey, dated as of September 1, 1997, filed by us as an Exhibit to our annual report on Form 20-F for the fiscal year
ended December 31, 2000, as filed with the Securities and Exchange Commission on June 30, 2001, and incorporated herein by reference.
|
| (*) |
Filed herewith.
|
|
|
SILICOM LIMITED
By:
/s/ Shaike Orbach
Shaike Orbach
Chief Executive Officer
|
|
Page
|
||
|
F - 3
|
||
|
F - 5
|
||
|
F - 7
|
||
|
F - 8
|
||
|
F - 9
|
||
|
F - 10
|
|
|
|
2018
|
2019
|
|||||||||||
|
Note
|
US$ thousands
|
US$ thousands
|
||||||||||
|
Assets
|
||||||||||||
|
Current assets
|
||||||||||||
|
Cash and cash equivalents
|
4
|
26,808
|
16,469
|
|||||||||
|
Short-term bank deposits
|
2F
|
|
-
|
13,542
|
||||||||
|
Marketable securities
|
2G, 5
|
1,600
|
14,045
|
|||||||||
|
Accounts receivable:
|
||||||||||||
|
Trade, net
|
2H
|
|
23,453
|
24,936
|
||||||||
|
Other
|
6
|
9,487
|
4,964
|
|||||||||
|
Related parties
|
364
|
-
|
||||||||||
|
Inventories
|
7
|
42,369
|
36,491
|
|||||||||
|
Total current assets
|
104,081
|
110,447
|
||||||||||
|
Marketable securities
|
2G, 5
|
45,612
|
46,542
|
|||||||||
|
Assets held for employees' severance benefits
|
11
|
1,517
|
1,640
|
|||||||||
|
Deferred tax assets
|
15G
|
|
894
|
1,798
|
||||||||
|
Property, plant and equipment, net
|
8
|
3,670
|
3,574
|
|||||||||
|
Intangible assets, net
|
9
|
966
|
1,718
|
|||||||||
|
Operating leases right-of-use, net
|
10
|
-
|
3,783
|
|||||||||
|
Goodwill
|
25,561
|
25,561
|
||||||||||
|
Total assets
|
182,301
|
195,063
|
||||||||||
|
Avi Eizenman
|
Shaike Orbach
|
Eran Gilad
|
||
|
Chairman of the Board of Directors
|
Chief Executive Officer
|
Chief Financial Officer
|
|
Consolidated Balance Sheets as of December 31 (Continued)
|
|
2018
|
2019
|
|||||||||||
|
Note
|
US$ thousands
|
US$ thousands
|
||||||||||
|
Liabilities and shareholders' equity
|
||||||||||||
|
Current liabilities
|
||||||||||||
|
Trade accounts payable
|
15,389
|
16,419
|
||||||||||
|
Other accounts payable and accrued expenses
|
6,133
|
8,823
|
||||||||||
|
Operating lease liabilities
|
10
|
-
|
1,090
|
|||||||||
|
Related parties
|
18
|
-
|
||||||||||
|
Total current liabilities
|
21,540
|
26,332
|
||||||||||
|
Long-term liabilities
|
||||||||||||
|
Operating lease liabilities
|
10
|
-
|
2,693
|
|||||||||
|
Liability for employees' severance benefits
|
11
|
2,612
|
2,910
|
|||||||||
|
Deferred tax liabilities
|
15G
|
|
-
|
205
|
||||||||
|
Total liabilities
|
24,152
|
32,140
|
||||||||||
|
Shareholders' equity
|
12
|
|||||||||||
|
Ordinary shares, ILS 0.01 par value; 10,000,000 shares
|
||||||||||||
|
authorized; 7,574,176 and 7,618,676 issued as at
|
||||||||||||
|
December 31, 2018 and 2019, respectively;
|
||||||||||||
|
7,559,205 and 7,351,317 outstanding as at
|
||||||||||||
|
December 31, 2018 and 2019, respectively
|
22
|
22
|
||||||||||
|
Additional paid-in capital
|
54,621
|
57,130
|
||||||||||
|
Treasury shares (at cost) - 14,971 and 267,359 ordinary shares as at
|
||||||||||||
|
December 31, 2018 and 2019, respectively
|
(38
|
)
|
(8,009
|
)
|
||||||||
|
Retained earnings
|
103,544
|
113,780
|
||||||||||
|
Total shareholders' equity
|
158,149
|
162,923
|
||||||||||
|
Total liabilities and shareholders’ equity
|
182,301
|
195,063
|
||||||||||
|
|
|
2017
|
2018
|
2019
|
||||||||||||||
|
US$ thousands
|
||||||||||||||||
|
Note
|
Except for share and per share data
|
|||||||||||||||
|
Sales*
|
2O, 13
|
125,690
|
133,753
|
105,240
|
||||||||||||
|
Cost of sales
|
79,762
|
91,697
|
69,146
|
|||||||||||||
|
Gross profit
|
45,928
|
42,056
|
36,094
|
|||||||||||||
|
Operating expenses
|
||||||||||||||||
|
Research and development**
|
13,915
|
14,820
|
15,075
|
|||||||||||||
|
Sales and marketing
|
6,722
|
6,642
|
6,647
|
|||||||||||||
|
General and administrative
|
4,507
|
3,943
|
4,159
|
|||||||||||||
|
Contingent consideration
|
3
|
(4,642
|
)
|
-
|
-
|
|||||||||||
|
Total operating expenses
|
20,502
|
25,405
|
25,881
|
|||||||||||||
|
Operating income
|
25,426
|
16,651
|
10,213
|
|||||||||||||
|
Financial income, net
|
14
|
156
|
923
|
1,646
|
||||||||||||
|
Income before income taxes
|
25,582
|
17,574
|
11,859
|
|||||||||||||
|
Income taxes
|
15
|
3,868
|
2,937
|
1,623
|
||||||||||||
|
Net income
|
21,714
|
14,637
|
10,236
|
|||||||||||||
|
Income per share:
|
||||||||||||||||
|
Basic income per ordinary share (US$)
|
2U
|
|
2.912
|
1.938
|
1.361
|
|||||||||||
|
Diluted income per ordinary share (US$)
|
2.856
|
1.912
|
1.352
|
|||||||||||||
|
Weighted average number of ordinary
|
||||||||||||||||
|
shares used to compute basic income
|
||||||||||||||||
|
per share (in thousands)
|
7,456
|
7,552
|
7,520
|
|||||||||||||
|
Weighted average number of ordinary
|
||||||||||||||||
|
shares used to compute diluted income
|
||||||||||||||||
|
per share (in thousands)
|
7,602
|
7,657
|
7,573
|
|||||||||||||
|
Ordinary shares
|
Additional paid-in capital
|
Treasury shares
|
Retained earnings
|
Total shareholders’ equity
|
||||||||||||||||||||
|
Number
of shares
(1)
|
US$ thousands
|
|||||||||||||||||||||||
|
Balance at
|
||||||||||||||||||||||||
|
January 1, 2017
|
7,381,613
|
22
|
46,833
|
(38
|
)
|
74,575
|
121,392
|
|||||||||||||||||
|
Exercise of options and RSUs
(2)
|
167,918
|
*-
|
2,651
|
-
|
-
|
2,651
|
||||||||||||||||||
|
Share-based compensation
|
-
|
-
|
2,425
|
-
|
-
|
2,425
|
||||||||||||||||||
|
Dividend (US $1.00 per share)
|
-
|
-
|
-
|
-
|
(7,382
|
)
|
(7,382
|
)
|
||||||||||||||||
|
Net income
|
-
|
-
|
-
|
-
|
21,714
|
21,714
|
||||||||||||||||||
|
Balance at
|
||||||||||||||||||||||||
|
December 31, 2017
|
7,549,531
|
22
|
51,909
|
(38
|
)
|
88,907
|
140,800
|
|||||||||||||||||
|
Exercise of options and RSUs
(2)
|
9,674
|
*-
|
288
|
-
|
-
|
288
|
||||||||||||||||||
|
Share-based compensation
|
-
|
-
|
2,424
|
-
|
-
|
2,424
|
||||||||||||||||||
|
Net income
|
-
|
-
|
-
|
-
|
14,637
|
14,637
|
||||||||||||||||||
|
Balance at
|
||||||||||||||||||||||||
|
December 31, 2018
|
7,559,205
|
22
|
54,621
|
(38
|
)
|
103,544
|
158,149
|
|||||||||||||||||
|
Exercise of options and RSUs
(2)
|
44,500
|
*-
|
154
|
-
|
-
|
154
|
||||||||||||||||||
|
Purchase of treasury shares
|
(252,388
|
)
|
-
|
-
|
(7,971
|
)
|
-
|
(7,971
|
)
|
|||||||||||||||
|
Share-based compensation
|
-
|
-
|
2,355
|
-
|
-
|
2,355
|
||||||||||||||||||
|
Net income
|
-
|
-
|
-
|
-
|
10,236
|
10,236
|
||||||||||||||||||
|
Balance at
|
||||||||||||||||||||||||
|
December 31, 2019
|
7,351,317
|
22
|
57,130
|
(8,009
|
)
|
113,780
|
162,923
|
|||||||||||||||||
|
(1)
|
Net of shares held by Silicom Inc. and Silicom Ltd.
|
|||||||||||||||||||||
|
(2)
|
Restricted share units (hereinafter - "RSUs")
|
|||||||||||||||||||||
|
*
|
Less than 1 thousand.
|
|||||||||||||||||||||
|
|
|
2017
|
2018
|
2019
|
||||||||||
|
US$ thousands
|
||||||||||||
|
Cash flows from operating activities
|
||||||||||||
|
Net income
|
21,714
|
14,637
|
10,236
|
|||||||||
|
Adjustments required to reconcile net income to
|
||||||||||||
|
net cash provided by (used in) operating activities:
|
||||||||||||
|
Depreciation and amortization
|
3,799
|
3,293
|
1,997
|
|||||||||
|
Write-down of obsolete inventory
|
2,918
|
6,211
|
2,106
|
|||||||||
|
Discount on marketable securities, net
|
217
|
32
|
144
|
|||||||||
|
Share-based compensation expense
|
2,425
|
2,424
|
2,355
|
|||||||||
|
Deferred taxes, net
|
453
|
5
|
(699
|
)
|
||||||||
|
Changes in assets and liabilities:
|
||||||||||||
|
Accounts receivable - trade
|
(13,237
|
)
|
16,985
|
(1,441
|
)
|
|||||||
|
Accounts receivable - other
|
(2,475
|
)
|
(3,384
|
)
|
4,385
|
|||||||
|
Accounts receivable - related parties
|
(208
|
)
|
261
|
364
|
||||||||
|
Change in liability for employees' severance benefits, net
|
171
|
(79
|
)
|
175
|
||||||||
|
Inventories
|
(10,287
|
)
|
2,540
|
3,529
|
||||||||
|
Trade accounts payable
|
1,698
|
3,059
|
769
|
|||||||||
|
Other accounts payable and accrued expenses
|
(1,144
|
)
|
(314
|
)
|
2,824
|
|||||||
|
Contingent consideration benefit
|
(4,642
|
)
|
-
|
-
|
||||||||
|
Accounts payable - related parties
|
6
|
8
|
(18
|
)
|
||||||||
|
Net cash provided by operating activities
|
1,408
|
45,678
|
26,726
|
|||||||||
|
Cash flows from investing activities
|
||||||||||||
|
Investment in short-term bank deposits, net
|
-
|
-
|
(13,542
|
)
|
||||||||
|
Purchase of property, plant and equipment
|
(1,690
|
)
|
(1,345
|
)
|
(1,441
|
)
|
||||||
|
Investment in intangible assets
|
(11
|
)
|
(1,022
|
)
|
(1,018
|
)
|
||||||
|
Proceeds from maturity of marketable securities
|
16,175
|
7,750
|
1,997
|
|||||||||
|
Purchases of marketable securities
|
(5,961
|
)
|
(41,670
|
)
|
(15,604
|
)
|
||||||
|
Net cash provided by (used in) investing activities
|
8,513
|
(36,287
|
)
|
(29,608
|
)
|
|||||||
|
Cash flows from financing activities
|
||||||||||||
|
Exercise of options
|
2,651
|
288
|
154
|
|||||||||
|
Dividend
|
(7,382
|
)
|
-
|
-
|
||||||||
|
Purchase of treasury shares
|
-
|
-
|
(7,971
|
)
|
||||||||
|
Net cash provided by (used in) financing activities
|
(4,731
|
)
|
288
|
(7,817
|
)
|
|||||||
|
Effect of exchange rate changes on cash balances held
|
(86
|
)
|
108
|
360
|
||||||||
|
Increase (decrease) in cash and cash equivalents
|
5,104
|
9,787
|
(10,339
|
)
|
||||||||
|
Cash and cash equivalents at beginning of year
|
11,917
|
17,021
|
26,808
|
|||||||||
|
Cash and cash equivalents at end of year
|
17,021
|
26,808
|
16,469
|
|||||||||
|
Supplementary cash flow information
|
||||||||||||
|
A. Non-cash transactions:
|
||||||||||||
|
Investments in property, plant and equipment
|
119
|
146
|
97
|
|||||||||
|
B. Cash paid during the year for:
|
||||||||||||
|
Income taxes
|
4,584
|
3,260
|
1,103
|
|||||||||
| A. |
Financial statements in US dollars
|
| B. |
Basis of presentation
|
| C. |
Estimates and assumptions
|
| D. |
Business combinations
|
| E. |
Cash and cash equivalents
|
| F. |
Short-term bank deposits
|
| G. |
Marketable securities
|
| H. |
Trade accounts receivable, net
|
| I. |
Inventories
|
| J. |
Assets held for employees’ severance benefits
|
| K. |
Property, plant and equipment
|
|
%
|
||
|
Machinery and equipment
|
15 - 33
|
|
|
Office furniture and equipment
|
6 - 33
|
|
|
Leasehold improvements
|
*
|
|
| L. |
Goodwill and other intangible assets
|
| M. |
Impairment of Long-Lived Assets
|
| N. |
Leases
|
| • |
Not to reassess its prior conclusions regarding lease identification, lease classification and initial direct costs under the new standard.
|
| • |
Applying the practical expedient pertaining to the use-of hindsight.
|
| • |
Short-term lease recognition exemption for all leases with a term shorter than 12 months. This means, that for those leases, the Company does not recognize ROU assets or lease liabilities but recognizes lease expenses over
the lease term on a straight-line basis.
|
| • |
Applying the practical expedient to not separate lease and non-lease components for all of the Company’s leases, other than leases of real estate.
|
|
According to the previous accounting policy
|
The change
|
As presented according to Topic 842
|
||||||||||
|
US$ thousands
|
||||||||||||
|
Operating leases right-of-use
|
-
|
3,424
|
3,424
|
|||||||||
|
Prepaid expenses
|
90
|
(90
|
)
|
-
|
||||||||
|
Operating lease liabilities
|
-
|
(3,334
|
)
|
(3,334
|
)
|
|||||||
|
O.
|
Revenue recognition (cont’d)
|
|
P.
|
Research and development costs
|
|
Q.
|
Allowance for product warranty
|
|
R.
|
Treasury shares
|
|
S.
|
Income taxes
|
|
T.
|
Share-based compensation
|
|
U.
|
Basic and diluted earnings per share
|
|
Year ended December 31
|
||||||||||||
|
2017
|
2018
|
2019
|
||||||||||
|
Net income attributable to ordinary shares
|
||||||||||||
|
(US$ thousands)
|
21,714
|
14,637
|
10,236
|
|||||||||
|
Weighted average number of ordinary shares outstanding
|
||||||||||||
|
used in basic income per ordinary share calculation
|
7,455,528
|
7,552,094
|
7,520,389
|
|||||||||
|
Add assumed exercise of outstanding dilutive potential
|
||||||||||||
|
ordinary shares
|
146,443
|
105,236
|
52,228
|
|||||||||
|
Weighted average number of ordinary shares outstanding
|
||||||||||||
|
used in diluted income per ordinary share calculation
|
7,601,971
|
7,657,330
|
7,572,617
|
|||||||||
|
Basic income per ordinary shares (US$)
|
2.912
|
1.938
|
1.361
|
|||||||||
|
Diluted income per ordinary shares (US$)
|
2.856
|
1.912
|
1.352
|
|||||||||
|
Weighted average number of shares related to options
|
||||||||||||
|
and RSUs excluded from the diluted earnings per share
|
||||||||||||
|
calculation because of anti-dilutive effect
|
-
|
171,086
|
351,610
|
|||||||||
| (1) |
In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments, which significantly changes the way entities recognize impairment of many financial assets by requiring immediate recognition
of estimated credit losses expected to occur over their remaining life. This ASU is effective for annual and interim periods in fiscal years beginning after December 15, 2019. Early adoption is permitted for annual and interim
periods in fiscal years beginning after December 15, 2018. In November 2019, the FASB issued ASU 2019-11, which includes several amendments to the credit losses standard (ASU 2016-13), including amendments to the reporting of
expected recoveries. The Company is currently evaluating the impact of the provisions of ASU 2016-13 on its financial position, results of operations and cash flows.
|
| (2) |
In December 2019, the FASB issued ASU 2019-12, which removes certain exceptions for: recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. The ASU also
adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. This ASU is effective for annual periods in fiscal years
beginning after December 15, 2021, and interim periods in fiscal years beginning after December 15, 2022. The Company does not expect the adoption of ASU 2019-12 to have a material impact on its consolidated balance sheets,
results of operations, cash flows or presentation thereof.
|
| (3) |
In January 2017, the FASB issued ASU 2017-04, “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,” which eliminates the requirement to calculate the implied fair value of goodwill in
Step 2 of the goodwill impairment test. Under ASU 2017-04, goodwill impairment charges will be based on the excess of a reporting unit’s carrying amount over its fair value as determined in Step 1 of the testing. ASU 2017-04 is
effective for interim and annual testing dates after December 15, 2019, with early adoption permitted for interim and annual goodwill impairment testing dates after January 1, 2017. The Company does not expect the adoption of
ASU 2017-04 to have a material impact on its consolidated balance sheets, results of operations, cash flows or presentation thereof.
|
|
|
A. |
ADI Engineering, Inc.
|
|
|
B. |
Silicom Denmark
|
|
Note 4 - Cash and Cash Equivalents
|
|
December 31
|
||||||||
|
2018
|
2019
|
|||||||
|
US$ thousands
|
||||||||
|
Cash
|
16,147
|
13,382
|
||||||
|
Cash equivalents *
|
10,661
|
3,087
|
||||||
|
26,808
|
16,469
|
|||||||
|
*
|
Comprised mainly of deposits in banks as at December 31, 2018 and 2019 carrying a weighted average interest rate of 2.79% and 1.04%, respectively.
|
|
Note 5 - Marketable Securities
|
|||||||||
|
Gross
|
Gross
|
|||||||||||||||
|
unrealized
|
unrealized
|
|||||||||||||||
|
Amortized
|
holding
|
holding
|
Aggregate
|
|||||||||||||
|
cost basis**
|
gains
|
(losses)
|
fair value*
|
|||||||||||||
|
US$ thousands
|
||||||||||||||||
|
At December 31, 2019
|
||||||||||||||||
|
Held to maturity:
|
||||||||||||||||
|
Corporate debt securities and government debt securities
|
||||||||||||||||
|
Current
|
14,170
|
24
|
(97
|
)
|
14,097
|
|||||||||||
|
Non-Current
|
46,955
|
408
|
(112
|
)
|
47,251
|
|||||||||||
|
61,125
|
432
|
(209
|
)
|
61,348
|
||||||||||||
|
At December 31, 2018
|
||||||||||||||||
|
Held to maturity:
|
||||||||||||||||
|
Corporate debt securities and government debt securities
|
||||||||||||||||
|
Current
|
1,610
|
-
|
(22
|
)
|
1,588
|
|||||||||||
|
Non-Current
|
46,052
|
-
|
(778
|
)
|
45,274
|
|||||||||||
|
47,662
|
-
|
(800
|
)
|
46,862
|
||||||||||||
|
*
|
Fair value is being determined using quoted market prices in active markets (Level 2).
|
|
**
|
Including accrued interest in the amount of US$ 450 thousand and US$ 538 thousand as of December 31, 2018 and 2019 respectively.
The accrued interest is presented as part of other account receivable on the balance sheet.
|
|
Activity in marketable securities in 2019
|
US$ thousands
|
|||
|
Balance at January 1, 2019
|
47,662
|
|||
|
Purchases of marketable securities
|
15,604
|
|||
|
Discount on marketable securities, net
|
(144
|
)
|
||
|
Proceeds from maturity of marketable securities
|
(1,997
|
)
|
||
|
Balance at December 31, 2019
|
61,125
|
|||
|
Note 5 - Marketable Securities (Cont’d)
|
||||||||||||||||
|
Less than 12 months
|
12 months or more
|
Total
|
||||||||||||||||||||||
|
Unrealized Losses
|
Fair value
|
Unrealized Losses
|
Fair value
|
Unrealized Losses
|
Fair value
|
|||||||||||||||||||
|
Held to maturity:
|
||||||||||||||||||||||||
|
Corporate debt securities and government debt securities
|
(38
|
)
|
4,968
|
(171
|
)
|
20,100
|
(209
|
)
|
25,068
|
|||||||||||||||
|
Note 6 - Other Receivables
|
|
December 31
|
||||||||
|
2018
|
2019
|
|||||||
|
US$ thousands
|
||||||||
|
Advances to suppliers
|
5,260
|
805
|
||||||
|
Government authorities
|
2,916
|
2,758
|
||||||
|
Prepaid expense
|
884
|
553
|
||||||
|
Other receivables
|
427
|
848
|
||||||
|
9,487
|
4,964
|
|||||||
|
|
||||||||
|
December 31
|
||||||||
|
2018
|
2019
|
|||||||
|
US$ thousands
|
||||||||
|
Raw materials and components
|
19,088
|
20,986
|
||||||
|
Products in process
|
10,883
|
7,137
|
||||||
|
Finished products
|
12,398
|
8,368
|
||||||
|
42,369
|
36,491
|
|||||||
|
December 31
|
||||||||
|
2018
|
2019
|
|||||||
|
US$ thousands
|
||||||||
|
Machinery and equipment
|
12,150
|
13,374
|
||||||
|
Office furniture and equipment
|
725
|
924
|
||||||
|
Leasehold improvements
|
2,375
|
2,528
|
||||||
|
Property, plant and equipment
|
15,250
|
16,826
|
||||||
|
Accumulated depreciation
|
(11,580
|
)
|
(13,252
|
)
|
||||
|
Property, Plant and equipment, net
|
3,670
|
3,574
|
||||||
|
Note 9 - Intangible Assets
|
|||||||||
|
December 31
|
||||||||||||
|
2018
|
2019
|
|||||||||||
|
Useful life
|
US$ thousands
|
|||||||||||
|
Original cost:
|
||||||||||||
|
Capitalization of software development costs
|
3
|
928
|
1,946
|
|||||||||
|
Licenses
|
3
|
106
|
106
|
|||||||||
|
1,034
|
2,052
|
|||||||||||
|
Accumulated amortization:
|
||||||||||||
|
Capitalization of software development costs
|
37
|
274
|
||||||||||
|
Licenses
|
31
|
60
|
||||||||||
|
68
|
334
|
|||||||||||
|
Intangible assets, Net:
|
||||||||||||
|
Capitalization of software development costs
|
891
|
1,672
|
||||||||||
|
Licenses
|
75
|
46
|
||||||||||
|
966
|
1,718
|
|||||||||||
|
Note 10 – Leases
|
|
A.
|
The components of operating lease cost for the year ended December 31, 2019 were as follows:
|
||||
|
Year ended
December 31
|
|||||
|
2019
|
|||||
|
US$ thousands
|
|||||
|
Operating lease cost
|
1,494
|
||||
|
Variable lease payments not included in the lease liability
|
2
|
||||
|
Short-term lease cost
|
287
|
||||
|
Total operating lease cost
|
1,783
|
||||
|
B.
|
Supplemental cash flow information related to operating leases was as follows:
|
||||
|
Year ended
December 31
|
|||||
|
2019
|
|||||
|
US$ thousands
|
|||||
|
Cash paid for amounts included in the measurement of lease liabilities:
|
|||||
|
Operating cash flows from operating leases
|
1,541
|
||||
|
Right-of-use assets obtained in exchange for lease obligations (non-cash):
|
|||||
|
Operating leases
|
1,524
|
||||
|
C.
|
Supplemental balance sheet information related to operating leases was as follows:
|
||||
|
December 31, 2019
|
|||||
|
US$ thousands
|
|||||
|
Operating leases:
|
|||||
|
Operating leases right-of-use
|
3,783
|
||||
|
Current operating lease liabilities
|
1,090
|
||||
|
Non-current operating lease liabilities
|
2,693
|
||||
|
Total operating lease liabilities
|
3,783
|
||||
|
December 31, 2019
|
|||||
|
US$ thousands
|
|||||
|
Weighted average remaining lease term
|
|||||
|
Operating leases
|
4.8 years
|
||||
|
Weighted average discount rate
|
|||||
|
Operating leases
|
3.3
|
%
|
|||
|
Note 10 – Leases (cont’d)
|
||||
|
D.
|
Future minimum lease payments under non-cancellable leases as of December 31, 2019 were as follows:
|
||||
|
December 31, 2019
|
|||||
|
US$ thousands
|
|||||
|
2020
|
1,209
|
||||
|
2021
|
831
|
||||
|
2022
|
641
|
||||
|
2023
|
576
|
||||
|
After 2024
|
709
|
||||
|
Total operating lease payments
|
3,966
|
||||
|
Less: imputed interest
|
(183
|
)
|
|||
|
Present value of lease liabilities
|
3,783
|
||||
|
E.
|
Future minimum lease payments under non-cancellable leases as of December 31, 2018, under ASC 840, Leases were as follows:
|
||||
|
December 31, 2018
|
|||||
|
US$ thousands
|
|||||
|
2019
|
1,394
|
||||
|
2020
|
643
|
||||
|
2021
|
449
|
||||
|
2022
|
363
|
||||
|
2023
|
363
|
||||
|
After 2024
|
643
|
||||
|
Total operating lease payments
|
3,855
|
||||
|
|
A . |
Under Israeli law and labor agreements, Silicom is required to make severance payments to retired or dismissed employees and to employees leaving employment in certain other circumstances.
|
|
|
B. |
According to Section 14 to the Severance Pay Law ("Section 14") the payment of monthly deposits by a company into recognized severance and pension funds or insurance policies releases it from any additional severance
obligation to the employees that have entered into agreements with the company pursuant to such Section 14. Commencing July 1, 2008, the Company has entered into agreements with a majority of its employees in order to implement
Section 14. Therefore, as of that date, the payment of monthly deposits by the Company into recognized severance and pension funds or insurance policies releases it from any additional severance obligation to those employees
that have entered into such agreements and therefore the Company incurs no additional liability since that date with respect to such employees. Amounts accumulated in the pension funds or insurance policies pursuant to Section
14 are not supervised or administrated by the Company and therefore neither such amounts nor the corresponding accrual are reflected in the balance sheet.
|
|
|
C . |
Consequently, the assets held for employees' severance benefits reported on the balance sheet, in respect of deposits for those employees who have signed agreements pursuant to Section 14, represent the redemption value of
deposits made through June 30, 2008. The liability for employee severance benefits, with respect to those employees, represents the liability of the Company for employees' severance benefits as of June 30, 2008.
|
|
|
D . |
Expenses recorded with respect to employees' severance payments for the years ended December 31, 2017, 2018 and 2019 were US$ 830 thousand, US$ 605 thousand and US$ 929 thousand, respectively.
|
|
|
A. |
On October 21, 2013 the Board resolved to adopt the Global Share Incentive Plan (2013) (the "2013 Plan") and to reserve up to 500,000 ordinary shares for issuance under the 2013 Plan to employees, directors, officers and
consultants of the Company or of any subsidiary or affiliate of the Company. In January 2018, our Board approved the increase of the number of ordinary shares reserved for issuance under the 2013 Plan by 600,000 additional
ordinary shares. Grants under the 2013 Plan, whether as options, restricted stock units, restricted stock or other equity based awards, including their terms, are subject to the Board of Directors' approval. Grants to directors
and certain other officers are generally subject to the approvals of the Compensation Committee as well as Board of Directors, and grants to directors or a CEO (and under certain circumstances certain other officers) will also
have to be approved by the Shareholders.
|
|
|
B. |
Options or RSUs granted to Israeli residents may be granted under Section 102 of the Israeli Income Tax Ordinance pursuant to which the awards of options, or the ordinary shares issued upon their exercise, must be deposited
with a trustee for at least two years following the date of grant. Under Section 102, any tax payable by an employee from the grant or exercise of the awards is deferred until the transfer of the awards or ordinary shares by the
trustee to the employee or upon the sale of the awards or ordinary shares.
|
|
|
C. |
During 2014, 2015 and 2017, the Company granted 74,000, 8,000 and 78,000 RSUs respectively to certain of its directors, employees and consultants under the 2013 Plan. In relation to those grants:
|
|
|
1. |
The vesting period of the RSUs ranges between 2 to 3 years from the date of grant.
|
|
|
2. |
The fair value of RSUs is estimated based on the market value of the Company’s stock on the date of grant, less an estimate of dividends that will not accrue to RSUs holders prior to vesting.
|
|
|
3. |
The Company recognizes compensation expenses on these RSUs based on estimated grant date fair value, with the following assumptions:
|
|
2014
|
2015
|
2017
|
||||||||||
|
Expected dividend yield
|
2.06
|
%
|
3.22
|
%
|
2.68
|
%
|
||||||
|
Termination rate
|
4.35
|
%
|
0
|
%
|
1.74
|
%
|
||||||
|
|
D. |
On July 28, 2015, the Company granted, in the aggregate, 89,907 options to certain of its directors and employees under the 2013 Plan. In relation to this grant:
|
|
|
1. |
The exercise price for the options (per ordinary share) was US$ 26.91 and the Option expiration date was the earlier to occur of: (a) July 28, 2023; and (b) the closing price of the shares falling below US$ 13.46 at any time
after the date of grant. The options vest and become exercisable on the second anniversary of the date of grant.
|
|
|
2. |
The Company recognizes compensation expenses on these options based on estimated grant date fair value using the Binomial option-pricing model with the following assumptions:
|
|
Average Risk-free interest rate
(a)
|
2.08
|
%
|
||
|
Expected dividend yield
|
2.09
|
%
|
||
|
Average expected volatility
(b)
|
53.01
|
%
|
||
|
Termination rate
|
9
|
%
|
||
|
Suboptimal factor
(c)
|
3.4
|
|
(a)
|
Risk-free interest rate represents risk free US$ zero-coupon US Government Bonds at time of grant.
|
|
(b)
|
Expected average volatility represents a weighted average standard deviation rate for the price of the Company’s ordinary shares on the NASDAQ National Market.
|
|
(c)
|
Suboptimal factor represents the multiple of the increase in the market share price on the day of grant of the option which, should it come to pass, will lead to exercise of the
option by the employee. It is the average suboptimal factor of the Company and similar companies.
|
|
|
1. |
The exercise price for the options (per ordinary share) was US$ 28.38 and the Option expiration date was the earlier to occur of: (a) June 8, 2024; and (b) the closing price of the shares falling below US$ 14.19 at any time
after the date of grant. The options vest and become exercisable on the second anniversary of the date of grant.
|
|
|
2. |
The Company recognizes compensation expenses on these options based on estimated grant date fair value using the Binomial option-pricing model with the following assumptions:
|
|
Average Risk-free interest rate
(a)
|
1.58
|
%
|
||
|
Expected dividend yield
|
2.42
|
%
|
||
|
Average expected volatility
(b)
|
47.90
|
%
|
||
|
Termination rate
|
9
|
%
|
||
|
Suboptimal factor
(c)
|
3.32
|
|
(a)
|
Risk-free interest rate represents risk free US$ zero-coupon US Government Bonds at time of grant.
|
|
(b)
|
Expected average volatility represents a weighted average standard deviation rate for the price of the Company’s ordinary shares on the NASDAQ National Market.
|
|
(c)
|
Suboptimal factor represents the multiple of the increase in the market share price on the day of grant of the option which, should it come to pass, will lead to exercise of the
option by the employee. It is the average suboptimal factor of the Company and similar companies.
|
|
|
F. |
On January 30, 2017, the Company granted, in the aggregate, 119,925 options to certain of its directors and employees under the 2013 Plan. In relation to this grant:
|
|
|
1. |
The exercise price for the options (per ordinary share) was US$ 39.62 and the Option expiration date was the earlier to occur of: (a) January 30, 2025; and (b) the closing price of the shares falling below US$ 19.81 at any
time after the date of grant. The options vest and become exercisable on the second anniversary of the date of grant.
|
|
|
2. |
The Company recognizes compensation expenses on these options based on estimated grant date fair value using the Binomial option-pricing model with the following assumptions:
|
|
Average Risk-free interest rate
(a)
|
2.35
|
%
|
||
|
Expected dividend yield
|
2.42
|
%
|
||
|
Average expected volatility
(b)
|
43.71
|
%
|
||
|
Termination rate
|
9
|
%
|
||
|
Suboptimal factor
(c)
|
3.28
|
|
(a)
|
Risk-free interest rate represents risk free US$ zero-coupon US Government Bonds at time of grant.
|
|
(b)
|
Expected average volatility represents a weighted average standard deviation rate for the price of the Company’s ordinary shares on the NASDAQ National Market.
|
|
(c)
|
Suboptimal factor represents the multiple of the increase in the market share price on the day of grant of the option which, should it come to pass, will lead to exercise of the
option by the employee. It is the average suboptimal factor of the Company and similar companies.
|
|
|
G. |
On April 30, 2018, the Company granted, in the aggregate, 137,010 options to certain of its directors and employees under the 2013 Plan. In relation to this grant:
|
|
|
1. |
The exercise price for the options (per ordinary share) was US$ 36.11 and the Option expiration date was the earlier to occur of: (a) April 30, 2026; and (b) the closing price of the shares falling below US$ 18.06 at any time
after the date of grant. The options vest and become exercisable on the second anniversary of the date of grant.
|
|
|
2. |
The Company recognizes compensation expenses on these options based on estimated grant date fair value using the Binomial option-pricing model with the following assumptions:
|
|
Average Risk-free interest rate
(a)
|
2.92
|
%
|
||
|
Expected dividend yield
|
0.0
|
%
|
||
|
Average expected volatility
(b)
|
45.13
|
%
|
||
|
Termination rate
|
9
|
%
|
||
|
Suboptimal factor
(c)
|
3.2
|
|
(a)
|
Risk-free interest rate represents risk free US$ zero-coupon US Government Bonds at time of grant.
|
|
(b)
|
Expected average volatility represents a weighted average standard deviation rate for the price of the Company’s ordinary shares on the NASDAQ National Market.
|
|
(c)
|
Suboptimal factor represents the multiple of the increase in the market share price on the day of grant of the option which, should it come to pass, will lead to exercise of the
option by the employee. It is the average suboptimal factor of the Company and similar companies.
|
|
|
H. |
On January 31, 2019, the Company granted, in the aggregate, 141,928 options to certain of its directors and employees under the 2013 Plan. In relation to this grant:
|
|
|
1. |
The exercise price for the options (per ordinary share) was US$ 33.83 and the Option expiration date was the earlier to occur of: (a) January 31, 2027; and (b) the closing price of the shares falling below US$ 16.92 at any
time after the date of grant. The options vest and become exercisable on the second anniversary of the date of grant.
|
|
|
2. |
The Company recognizes compensation expenses on these options based on estimated grant date fair value using the Binomial option-pricing model with the following assumptions:
|
|
Average Risk-free interest rate
(a)
|
2.55
|
%
|
||
|
Expected dividend yield
|
0.0
|
%
|
||
|
Average expected volatility
(b)
|
44.62
|
%
|
||
|
Termination rate
|
9
|
%
|
||
|
Suboptimal factor
(c)
|
3.18
|
|
(a)
|
Risk-free interest rate represents risk free US$ zero-coupon US Government Bonds at time of grant.
|
|
(b)
|
Expected average volatility represents a weighted average standard deviation rate for the price of the Company’s ordinary shares on the NASDAQ National Market.
|
|
(c)
|
Suboptimal factor represents the multiple of the increase in the market share price on the day of grant of the option which, should it come to pass, will lead to exercise of the
option by the employee. It is the average suboptimal factor of the Company and similar companies.
|
|
|
I.
|
The following table summarizes information regarding stock options as at December 31, 2019:
|
|
Options outstanding
|
Options exercisable
|
||||||||||||||||
|
Weighted average
|
Weighted average
|
||||||||||||||||
|
remaining
|
remaining
|
||||||||||||||||
|
Exercise price
|
Number
|
contractual life
|
Number
|
contractual life
|
|||||||||||||
|
US$
|
of options
|
(in years)
|
of options
|
(in years)
|
|||||||||||||
|
15.28
|
6,575
|
0.7
|
6,575
|
0.7
|
|||||||||||||
|
26.91
|
19,332
|
3.6
|
19,332
|
3.6
|
|||||||||||||
|
33.27
|
19,706
|
6.3
|
19,706
|
6.3
|
|||||||||||||
|
28.38
|
72,198
|
4.4
|
72,198
|
4.4
|
|||||||||||||
|
39.62
|
101,838
|
5.1
|
101,838
|
5.1
|
|||||||||||||
|
36.11
|
116,257
|
6.3
|
-
|
-
|
|||||||||||||
|
33.83
|
129,341
|
7.1
|
-
|
-
|
|||||||||||||
|
465,247
|
219,649
|
||||||||||||||||
|
Note 12 - Shareholders' Equity (cont'd)
|
|
|
J.
|
The stock option activity under the abovementioned plans is as follows:
|
|
Weighted
|
||||||||||||
|
Weighted
|
average
|
|||||||||||
|
Number
|
average
|
grant date
|
||||||||||
|
of options
|
exercise price
|
fair value
|
||||||||||
|
US$
|
US$
|
|||||||||||
|
Balance at January 1, 2017
|
266,005
|
|||||||||||
|
Granted
|
119,925
|
39.62
|
11.89
|
|||||||||
|
Exercised
|
(124,918
|
)
|
21.46
|
8.46
|
||||||||
|
Forfeited
|
(11,101
|
)
|
33.18
|
10.87
|
||||||||
|
Balance at December 31, 2017
|
249,911
|
|||||||||||
|
Granted
|
137,010
|
36.11
|
14.71
|
|||||||||
|
Exercised
|
(9,674
|
)
|
28.02
|
9.94
|
||||||||
|
Forfeited
|
(11,752
|
)
|
36.73
|
13.05
|
||||||||
|
Balance at December 31, 2018
|
365,495
|
|||||||||||
|
Granted
|
141,928
|
33.83
|
13.35
|
|||||||||
|
Exercised
|
(5,500
|
)
|
28.09
|
10.03
|
||||||||
|
Forfeited
|
(36,676
|
)
|
35.88
|
13.50
|
||||||||
|
Balance at December 31, 2019
|
465,247
|
|||||||||||
|
Exercisable at December 31, 2019
|
219,649
|
|||||||||||
|
|
K.
|
The Restricted Share Units activity under the abovementioned plans is as follows:
|
|
Weighted
|
||||||||
|
Number of
|
average
|
|||||||
|
Restricted
|
grant date
|
|||||||
|
Share Units
|
fair value
|
|||||||
|
US$
|
||||||||
|
Balance at January 1, 2017
|
43,000
|
|||||||
|
Granted
|
78,000
|
34.90
|
||||||
|
Vested
|
(43,000
|
)
|
42.52
|
|||||
|
Balance at December 31, 2017 and December 31, 2018
|
78,000
|
|||||||
|
Vested
|
(39,000
|
)
|
35.36
|
|||||
|
Balance at December 31, 2019
|
39,000
|
|||||||
|
|
L.
|
During 2017, 2018 and 2019, the Company recorded share-based compensation expenses. The following summarizes the allocation of the stock-based compensation
expenses:
|
|
Year ended December 31
|
||||||||||||
|
2017
|
2018
|
2019
|
||||||||||
|
US$ thousands
|
||||||||||||
|
Cost of sales
|
320
|
372
|
437
|
|||||||||
|
Research and development costs
|
832
|
953
|
900
|
|||||||||
|
Selling and marketing expenses
|
537
|
569
|
493
|
|||||||||
|
General and administrative expenses
|
736
|
530
|
525
|
|||||||||
|
2,425
|
2,424
|
2,355
|
||||||||||
|
A.
|
Information on sales by geographic distribution:
|
|
Year ended December 31
|
||||||||||||
|
2017
|
2018
|
2019
|
||||||||||
|
US$ thousands
|
||||||||||||
|
North America
|
100,434
|
108,024
|
77,161
|
|||||||||
|
Europe
|
20,156
|
21,038
|
20,956
|
|||||||||
|
Asia-Pacific
|
5,100
|
4,691
|
7,123
|
|||||||||
|
125,690
|
133,753
|
105,240
|
||||||||||
|
B.
|
Sales to single customers exceeding 10% of sales (US$ thousands):
|
|
Year ended December 31
|
||||||||||||
|
2017
|
2018
|
2019
|
||||||||||
|
US$ thousands
|
||||||||||||
|
Customer "A"
|
16,915
|
18,855
|
17,107
|
|||||||||
|
Customer "B"
|
*
|
14,506
|
11,030
|
|||||||||
|
Customer "C"
|
*
|
14,220
|
*
|
|||||||||
|
Customer "D"
|
25,888
|
*
|
*
|
|||||||||
|
*
|
Less than 10% of sales.
|
|
C.
|
Information on Long-Lived Assets - Property, Plant and Equipment and ROU assets by geographic areas:
|
|
Year ended December 31
|
||||||||
|
2018
|
*2019
|
|||||||
|
US$ thousands
|
||||||||
|
North America
|
46
|
1,189
|
||||||
|
Europe
|
235
|
198
|
||||||
|
Israel
|
3,389
|
5,970
|
||||||
|
3,670
|
7,357
|
|||||||
|
Year ended December 31
|
||||||||||||
|
2017
|
2018
|
2019
|
||||||||||
|
US$ thousands
|
||||||||||||
|
Interest income
|
527
|
840
|
2,295
|
|||||||||
|
Discount on marketable securities, net
|
(217
|
)
|
(32
|
)
|
(144
|
)
|
||||||
|
Exchange rate differences, net
|
(45
|
)
|
208
|
(357
|
)
|
|||||||
|
Bank charges
|
(109
|
)
|
(93
|
)
|
(148
|
)
|
||||||
|
156
|
923
|
1,646
|
||||||||||
|
|
A. |
Measurement of results for tax purposes under the Israeli Income Tax Regulations (Rules for Maintaining Accounting Records of Foreign Invested Companies and Certain Partnerships and Determining
Their Taxable Income) - 1986
|
|
|
B. |
Corporate tax rate in Israel
|
|
|
C. |
Tax benefits under the Israeli Law for the Encouragement of Capital Investments, 1959 (hereinafter - the "Law")
|
|
|
1. |
On December 29, 2010 the Knesset approved the Economic Policy Law for 2011-2012, which includes an amendment to the Law for the Encouragement of Capital Investments – 1959 (hereinafter – "the Amendment to the Law"). The
Amendment to the Law is effective from January 1, 2011 and its provisions will apply to preferred income derived or accrued in 2011 and thereafter by a Preferred Company, per the definition of these terms in the Amendment to
the Law.
|
|
|
C. |
Tax benefits under the Israeli Law for the Encouragement of Capital Investments, 1959 (hereinafter - the "Law") (cont'd)
|
|
|
2. |
In the event of distribution by the Company of dividends out of its retained earnings that were generated prior to 2014 tax year and were tax exempt under the "Approved Enterprise" or "Benefited Enterprise" status, the
Company would be subjected to a maximum of 25% corporate tax on the amount distributed, and a further 15% withholding tax would be deducted from the amounts distributed to the shareholders.
|
|
|
1. |
The subsidiary Silicom Inc. files tax returns to US federal tax authorities and to state tax authorities in the states of New Jersey, California, Virginia, New York, New Mexico, Tennessee and Texas.
|
|
|
2. |
The subsidiary Silicom Denmark is taxed according to the tax laws in Denmark.
|
|
|
3. |
The Company has not provided for Israeli income and foreign withholding taxes on US$ 7,221 thousand of its non-Israeli subsidiaries' undistributed earnings as of December 31, 2019. The earnings could become subject to tax
if earnings are remitted or deemed remitted as dividends or upon sale of a subsidiary.
|
|
|
4. |
As of December 31, 2019, the net operating loss carry-forwards of the Companys’ subsidiaries for tax purposes amounted to approximately US$ 900 thousand. These losses are available to offset any future taxable income.
|
|
|
1. |
For the Israeli jurisdiction the Company has final tax assessments for all years up to and including the tax year ended December 31, 2014.
|
|
|
2. |
For the US Federal jurisdiction, Silicom Inc. has final tax assessments for all years up to and including the tax year ended December 31, 2015. For the New Jersey and California state jurisdictions, Silicom Inc. has final
tax assessments for all years up to and including the tax year ended December 31, 2014. For the Virginia state jurisdiction, Silicom Inc. has open tax assessments for the years 2016 through 2019. For the Tennessee state
jurisdiction, Silicom Inc. has open tax assessments for the years 2016 through 2019. For the New Mexico and New York state jurisdictions, Silicom Inc. has open tax assessments for the years 2017 through 2019. For the Texas
state jurisdiction, Silicom Inc. has open tax assessments for the years 2018 and 2019.
|
|
|
3. |
For the Danish jurisdiction, Silicom Denmark has final tax assessments for all years up to and including the tax year ended August 31, 2014.
|
|
F.
|
Income before income taxes and income taxes expense (benefit) included in the consolidated statements of operations
|
|
Year ended December 31
|
||||||||||||
|
2017
|
2018
|
2019
|
||||||||||
|
US$ thousands
|
||||||||||||
|
Income before income taxes:
|
||||||||||||
|
Israel
|
23,226
|
14,703
|
9,339
|
|||||||||
|
Foreign jurisdiction
|
2,356
|
2,871
|
2,520
|
|||||||||
|
25,582
|
17,574
|
11,859
|
||||||||||
|
Current taxes:
|
||||||||||||
|
Israel
|
2,379
|
2,400
|
1,732
|
|||||||||
|
Foreign jurisdiction
|
1,095
|
831
|
611
|
|||||||||
|
3,474
|
3,231
|
2,343
|
||||||||||
|
Current tax (benefits) expenses relating
|
||||||||||||
|
to prior years:
|
||||||||||||
|
Israel
|
12
|
(73
|
)
|
(17
|
)
|
|||||||
|
Foreign jurisdiction
|
(71
|
)
|
(226
|
)
|
(4
|
)
|
||||||
|
(59
|
)
|
(299
|
)
|
(21
|
)
|
|||||||
|
Deferred taxes:
|
||||||||||||
|
Israel
|
549
|
(106
|
)
|
(904
|
)
|
|||||||
|
Foreign jurisdiction
|
(96
|
)
|
111
|
205
|
||||||||
|
453
|
5
|
(699
|
)
|
|||||||||
|
Income tax expense
|
3,868
|
2,937
|
1,623
|
|||||||||
|
December 31
|
December 31
|
|||||||
|
2018
|
2019
|
|||||||
|
US$ thousands
|
US$ thousands
|
|||||||
|
Deferred tax assets:
|
||||||||
|
Accrued employee benefits
|
281
|
327
|
||||||
|
Research and development costs
|
842
|
1,597
|
||||||
|
Tax loss carryforwards
|
169
|
196
|
||||||
|
Property, plant and equipment
|
48
|
31
|
||||||
|
Share based compensation
|
348
|
374
|
||||||
|
Intangible assets
|
202
|
347
|
||||||
|
Other
|
23
|
-
|
||||||
|
Total gross deferred tax assets
|
1,913
|
2,872
|
||||||
|
Deferred tax liabilities:
|
||||||||
|
Intangible assets
|
(212
|
)
|
(397
|
)
|
||||
|
Goodwill
|
(807
|
)
|
(879
|
)
|
||||
|
Other
|
-
|
(3
|
)
|
|||||
|
Total gross deferred tax liabilities
|
(1,019
|
)
|
(1,279
|
)
|
||||
|
Net deferred tax assets
|
894
|
1,593
|
||||||
|
In Israel
|
894
|
1,798
|
||||||
|
Foreign jurisdictions
|
-
|
(205
|
)
|
|||||
|
Net deferred tax assets
|
894
|
1,593
|
||||||
|
Non-current deferred tax assets
|
894
|
1,798
|
||||||
|
Non-current deferred tax liabilities
|
-
|
(205
|
)
|
|||||
|
H.
|
Reconciliation of the statutory tax expense to actual tax expense
|
|
Year ended December 31
|
||||||||||||
|
2017
|
2018
|
2019
|
||||||||||
|
US$ thousands
|
||||||||||||
|
Income before income taxes
|
25,582
|
17,574
|
11,859
|
|||||||||
|
Statutory tax rate in Israel
|
24.0
|
%
|
23.0
|
%
|
23.0
|
%
|
||||||
|
6,140
|
4,042
|
2,728
|
||||||||||
|
Increase (decrease) in taxes resulting from:
|
||||||||||||
|
Non-deductible operating expenses, net
|
364
|
295
|
417
|
|||||||||
|
Non-taxable income
|
(1,114
|
)
|
-
|
-
|
||||||||
|
Prior years adjustments
|
(59
|
)
|
(299
|
)
|
(21
|
)
|
||||||
|
Tax effect due to
|
||||||||||||
|
"Preferred Enterprise" status*
|
(2,361
|
)
|
(1,398
|
)
|
(1,099
|
)
|
||||||
|
Taxes related to foreign jurisdictions
|
632
|
176
|
18
|
|||||||||
|
Changes in tax rate
|
162
|
-
|
7
|
|||||||||
|
Creation of deferred taxes for tax losses and
|
||||||||||||
|
benefits from previous years for which deferred
|
||||||||||||
|
taxes were not created in the past
|
-
|
-
|
(476
|
)
|
||||||||
|
Other
|
104
|
121
|
49
|
|||||||||
|
Income tax expense
|
3,868
|
2,937
|
1,623
|
|||||||||
|
Year ended December 31
|
||||||||||||
|
2017
|
2018
|
2019
|
||||||||||
|
Basic
|
0.32
|
0.19
|
0.15
|
|||||||||
|
Diluted
|
0.31
|
0.18
|
0.15
|
|||||||||
|
|
(1) |
In January 2020, the Company’s compensation committee and board of directors, respectively, have approved the grant of a total of 148,426 options and 86,000 RSUs under the Global Share Incentive Plan (2013), of which
options and RSUs granted to directors and office holders are subject to the approval of the Annual General Meeting, which is currently scheduled to convene no later than June 2020, as prescribed under the Israeli Companies
Law, 1999 and the Company's Amended and Restated Articles of Association.
|
|
|
(2) |
Pursuant to the share repurchase plan approved on May 2, 2019, the Company has purchased 97,577 shares of the Company's ordinary shares subsequent to December 31, 2019 and through March 6, 2020 for a total cost of US$
3,326 thousand inclusive of transaction costs, bringing the total shares repurchased under the plan to 349,965.
|
|
|
(3) |
In late December 2019, the World Health Organization was informed of a cluster of cases of pneumonia of unknown cause discovered in Wuhan, Hubei province, in China. A novel coronavirus
(COVID-19) was identified, with cases confirmed in multiple provinces in China as well as in other countries. The outbreak of such communicable diseases could result in a widespread health crisis that could adversely
affect the general commercial activity and the economies and financial markets of many countries. Although, to date, the Company did not experience any material adverse effects as a result of the ongoing novel
coronavirus, if it continues to spread, the Company’s operations could experience a slowdown or temporary suspension in production. In the event that the slowdown or suspension carries for a long period of time, the
Company’s business could be materially and adversely affected. Countries affected may adopt certain hygiene measures, including quarantining visitors from places where any of the contagious diseases were rampant. Any
prolonged restrictive measures taken by the governments of countries affected in order to control the contagious disease or other adverse public health developments may have a material and adverse effect on the
Company’s business, financial condition or results of operations.
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|